Date of submission of the HTAC Recommendation: 20 July 2026Date of notification to HTAC on the SOH decision: 26 August 2026 The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on levothyroxine sodium 12.5 micrograms (mcg) and 25 mcg tablets for the management of hypothyroidism of any etiology through Department continue reading : HTA Council Final Recommendation on levothyroxine sodium 12.5 micrograms (mcg) and 25 mcg tablets for the management of hypothyroidism of any etiology
HTA Council Final Recommendation on norepinephrine (as tartrate) 1mg/mL concentrate solution for IV infusion in 8mL ampule for cardiogenic or vascular shock that persists after adequate fluid volume replacement; severe hypotension; and, (as first-choice vasopressor) treatment of sepsis and septic shock in adults
Date of submission of the HTAC Recommendation: 20 July 2026Date of notification to HTAC on the SOH decision: 26 August 2026 The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on norepinephrine (as tartrate) 1mg/mL concentrate solution for IV infusion in 8mL ampule for cardiogenic or vascular shock that persists continue reading : HTA Council Final Recommendation on norepinephrine (as tartrate) 1mg/mL concentrate solution for IV infusion in 8mL ampule for cardiogenic or vascular shock that persists after adequate fluid volume replacement; severe hypotension; and, (as first-choice vasopressor) treatment of sepsis and septic shock in adults
HTA Council Preliminary Recommendation on trastuzumab 440 mg lyophilized powder for intravenous (IV) infusion for the treatment of HER-2 overexpressing early-stage breast cancer, taken alone or in combination with chemotherapy
As of 11 August 2026, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of trastuzumab 440 mg lyophilized powder for intravenous (IV) infusion for the treatment of HER-2 overexpressing early-stage breast cancer, taken alone or in combination with chemotherapy. The HTA Council hereby releases its preliminary recommendation on the continue reading : HTA Council Preliminary Recommendation on trastuzumab 440 mg lyophilized powder for intravenous (IV) infusion for the treatment of HER-2 overexpressing early-stage breast cancer, taken alone or in combination with chemotherapy
HTA Council Final Recommendation on ezetimibe [10 mg tablet] for the treatment of hyperlipidemia (with Secretary of Health Decision)
Date of submission of the HTAC Recommendation: 11 June 2026Date of notification to HTAC on the SOH decision: 30 July 2026 The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on ezetimibe [10 mg tablet] for the treatment of hyperlipidemia as an adjunct to maximally-tolerated statin therapy through Department of Health (DOH) continue reading : HTA Council Final Recommendation on ezetimibe [10 mg tablet] for the treatment of hyperlipidemia (with Secretary of Health Decision)
HTA Council Preliminary Recommendation on abiraterone acetate 500mg film-coated tablet as first-line treatment or second-line treatment for metastatic castration-resistant prostate cancer (mCRPC)
As of 14 July 2026, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of abiraterone acetate 500mg film-coated tablet as first-line treatment or second-line treatment for metastatic castration-resistant prostate cancer (mCRPC). The HTA Council hereby releases its preliminary recommendation on the said health technology for stakeholder feedback and comments continue reading : HTA Council Preliminary Recommendation on abiraterone acetate 500mg film-coated tablet as first-line treatment or second-line treatment for metastatic castration-resistant prostate cancer (mCRPC)